Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 195

1.

Secondary Malignancies Following Treatment for Hodgkin's Lymphoma in Childhood and Adolescence.

Dörffel W, Riepenhausenl M, Lüders H, Brämswig J, Schellong G.

Dtsch Arztebl Int. 2015 May 1;112(18):320-7, i. doi: 10.3238/arztebl.2015.0320.

2.

Parenthood in adult female survivors treated for Hodgkin's lymphoma during childhood and adolescence: a prospective, longitudinal study.

Brämswig JH, Riepenhausen M, Schellong G.

Lancet Oncol. 2015 Jun;16(6):667-75. doi: 10.1016/S1470-2045(15)70140-3. Epub 2015 May 7.

PMID:
25959806
3.

Consider family history. In reply.

Schellong G, Brämswig J.

Dtsch Arztebl Int. 2014 May 30;111(22):404. doi: 10.3238/arztebl.2014.0404. No abstract available.

4.

Breast cancer in young women after treatment for Hodgkin's disease during childhood or adolescence--an observational study with up to 33-year follow-up.

Schellong G, Riepenhausen M, Ehlert K, Brämswig J, Dörffel W; German Working Group on the Long-Term Sequelae of Hodgkin's Disease, Schmutzler RK, Rhiem K, Bick U; German Consortium for Hereditary Breast and Ovarian Cancer.

Dtsch Arztebl Int. 2014 Jan 6;111(1-2):3-9. doi: 10.3238/arztebl.2014.0003.

5.

Quality of life in long-term survivors following treatment for Hodgkin's disease during childhood and adolescence in the German multicentre studies between 1978 and 2002.

Calaminus G, Dörffel W, Baust K, Teske C, Riepenhausen M, Brämswig J, Flechtner HH, Singer S, Hinz A, Schellong G.

Support Care Cancer. 2014 Jun;22(6):1519-29. doi: 10.1007/s00520-013-2114-y. Epub 2014 Jan 12.

PMID:
24415000
6.

The impact of central review and central therapy planning on the treatment of children and adolescents with Hodgkin lymphoma.

Lüders H, Rühl U, Marciniak H, Haerting J, Claviez A, Mann G, Schellong G, Wickmann L, Dörffel W.

Eur J Cancer. 2014 Jan;50(2):425-33. doi: 10.1016/j.ejca.2013.09.017. Epub 2013 Oct 21.

PMID:
24157256
7.

Effective childhood cancer treatment: the impact of large scale clinical trials in Germany and Austria.

Rossig C, Juergens H, Schrappe M, Moericke A, Henze G, von Stackelberg A, Reinhardt D, Burkhardt B, Woessmann W, Zimmermann M, Gadner H, Mann G, Schellong G, Mauz-Koerholz C, Dirksen U, Bielack S, Berthold F, Graf N, Rutkowski S, Calaminus G, Kaatsch P, Creutzig U.

Pediatr Blood Cancer. 2013 Oct;60(10):1574-81. doi: 10.1002/pbc.24598. Epub 2013 Jun 5. Review.

PMID:
23737479
8.

Development of a curative treatment within the AML-BFM studies.

Creutzig U, Zimmermann M, Dworzak MN, Ritter J, Schellong G, Reinhardt D.

Klin Padiatr. 2013 May;225 Suppl 1:S79-86. doi: 10.1055/s-0033-1337968. Epub 2013 May 22. Review.

PMID:
23700063
9.

Treatment of children and adolescents with Hodgkin lymphoma without radiotherapy for patients in complete remission after chemotherapy: final results of the multinational trial GPOH-HD95.

Dörffel W, Rühl U, Lüders H, Claviez A, Albrecht M, Bökkerink J, Holte H, Karlen J, Mann G, Marciniak H, Niggli F, Schmiegelow K, Schwarze EW, Pötter R, Wickmann L, Schellong G.

J Clin Oncol. 2013 Apr 20;31(12):1562-8. doi: 10.1200/JCO.2012.45.3266. Epub 2013 Mar 18.

PMID:
23509321
10.

Mimicry of hydroxyurea-induced leg ulcer by distal vena saphena parva insufficiency.

Goerge T, Schellong G, Mesters RM, Berdel WE.

Ann Hematol. 2012 Mar;91(3):471-2. doi: 10.1007/s00277-011-1270-8. Epub 2011 Jun 7. No abstract available.

PMID:
21647582
11.

Late valvular and other cardiac diseases after different doses of mediastinal radiotherapy for Hodgkin disease in children and adolescents: report from the longitudinal GPOH follow-up project of the German-Austrian DAL-HD studies.

Schellong G, Riepenhausen M, Bruch C, Kotthoff S, Vogt J, Bölling T, Dieckmann K, Pötter R, Heinecke A, Brämswig J, Dörffel W.

Pediatr Blood Cancer. 2010 Dec 1;55(6):1145-52. doi: 10.1002/pbc.22664.

PMID:
20734400
12.

Resection alone in 58 children with limited stage, lymphocyte-predominant Hodgkin lymphoma-experience from the European network group on pediatric Hodgkin lymphoma.

Mauz-Körholz C, Gorde-Grosjean S, Hasenclever D, Shankar A, Dörffel W, Wallace WH, Schellong G, Robert A, Körholz D, Oberlin O, Hall GW, Landman-Parker J.

Cancer. 2007 Jul 1;110(1):179-85.

13.

Treatment strategies and long-term results in paediatric patients treated in four consecutive AML-BFM trials.

Creutzig U, Zimmermann M, Ritter J, Reinhardt D, Hermann J, Henze G, Jürgens H, Kabisch H, Reiter A, Riehm H, Gadner H, Schellong G.

Leukemia. 2005 Dec;19(12):2030-42.

PMID:
16304570
14.

Salvage therapy of progressive and recurrent Hodgkin's disease: results from a multicenter study of the pediatric DAL/GPOH-HD study group.

Schellong G, Dörffel W, Claviez A, Körholz D, Mann G, Scheel-Walter HG, Bökkerink JP, Riepenhausen M, Lüders H, Pötter R, Rühl U; DAL/GPOH.

J Clin Oncol. 2005 Sep 1;23(25):6181-9.

PMID:
16135485
15.

Proliferation characteristics in pediatric Hodgkin's lymphoma point to a cell cycle arrest in the G(1) phase.

Tiemann M, Claviez A, Lüders H, Zimmermann M, Schellong G, Dörffel W, Parwaresch R.

Mod Pathol. 2005 Nov;18(11):1440-7.

16.

Impact of latent Epstein-Barr virus infection on outcome in children and adolescents with Hodgkin's lymphoma.

Claviez A, Tiemann M, Lüders H, Krams M, Parwaresch R, Schellong G, Dörffel W.

J Clin Oncol. 2005 Jun 20;23(18):4048-56.

PMID:
15961758
17.
18.

The concept of the GPOH-HD 2003 therapy study for pediatric Hodgkin's disease: evolution in the tradition of the DAL/GPOH studies.

Körholz D, Claviez A, Hasenclever D, Kluge R, Hirsch W, Kamprad F, Dörffel W, Wickmann L, Papsdorf K, Dieckmann K, Kahn T, Mauz-Körholz C, Dannenberg C, Pötter R, Brosteanu O, Schellong G, Sabri O.

Klin Padiatr. 2004 May-Jun;216(3):150-6.

PMID:
15175959
19.

Immunodeficiency and Hodgkin's disease: treatment and outcome in the DAL HD78-90 and GPOH HD95 studies.

Niehues T, Schellong G, Dörffel W, Bucsky P, Mann G, Körholz D, Göbel U.

Klin Padiatr. 2003 Nov-Dec;215(6):315-20.

PMID:
14677095
20.

Preliminary results of the multicenter trial GPOH-HD 95 for the treatment of Hodgkin's disease in children and adolescents: analysis and outlook.

Dörffel W, Lüders H, Rühl U, Albrecht M, Marciniak H, Parwaresch R, Pötter R, Schellong G, Schwarze EW, Wickmann L.

Klin Padiatr. 2003 May-Jun;215(3):139-45.

PMID:
12838937

Supplemental Content

Loading ...
Support Center